Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.55 |
| ▸ | CTSK | P43235 | 2/20 | 0.55 |
| ▸ | REN | P00797 | 17/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | CTSE | P14091 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7319463 | 0.88 | CTSS (0.51) | CTSSCTSKRENCTSDCTSE | |
| SCHEMBL7284721 | 0.87 | CTSS (0.55) | CTSSCTSKRENCTSDCTSE | |
| SCHEMBL9726146 | 0.85 | CTSS (0.54) | CTSSCTSKRENCTSDCTSE | |
| SCHEMBL10386880 | 0.85 | CTSS (0.54) | CTSSCTSKRENCTSDCTSE | |
| SCHEMBL9831219 | 0.85 | CTSS (0.54) | CTSSCTSKRENCTSDCTSE | |
| SCHEMBL13306504 | 0.85 | CTSS (0.53) | CTSSCTSKRENCTSDCTSE | |
| SCHEMBL12920120 | 0.85 | CTSS (0.53) | CTSSCTSKRENCTSDCTSE | |
| SCHEMBL7272375 | 0.85 | CTSS (0.53) | CTSSCTSKRENCTSDCTSE | |
| SCHEMBL3606572 | 0.85 | CTSS (0.53) | CTSSCTSKRENCTSDCTSE | |
| SCHEMBL3606578 | 0.85 | CTSS (0.53) | CTSSCTSKRENCTSDCTSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | VITAE PHARMACEUTICALS, INC. | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | DNPEP, ACE, DPEP1 | CTSS 204/4885CTSK 175/4885REN 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.